Focused On-demand Library for Sodium-dependent phosphate transport protein 2C

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8N130

UPID:

NPT2C_HUMAN

Alternative names:

Na(+)-dependent phosphate cotransporter 2C; Sodium/inorganic phosphate cotransporter IIC; Sodium/phosphate cotransporter 2C; Solute carrier family 34 member 3

Alternative UPACC:

Q8N130; A2BFA1

Background:

Sodium-dependent phosphate transport protein 2C, also known as Na(+)-dependent phosphate cotransporter 2C, plays a crucial role in phosphate homeostasis by actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. This process is vital for maintaining the balance of phosphate in the body, which is essential for bone health and energy metabolism.

Therapeutic significance:

The protein is directly linked to Hereditary hypophosphatemic rickets with hypercalciuria, a disease characterized by reduced renal phosphate reabsorption and rickets. Understanding the role of Sodium-dependent phosphate transport protein 2C could open doors to potential therapeutic strategies for managing this condition and improving patient outcomes.